Skip to content

Alphamab Oncology Sustainability Reports

Alphamab Oncology is a clinical-stage biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative therapeutics for cancer treatment. Its portfolio primarily targets bispecific antibodies and antibody-drug conjugates (ADCs) to address unmet oncology clinical needs globally.

Sector: Manufacturing

Country: China

Exchange: Hong Kong Stock Exchange

LEI: 254900VOW925DTFGNA02

FIGI: BBG00QX1PZX2

21 reports from 2019 to 2025